arrow
A

Amy J. Sehnert

verinata health, inc.
H指数:40
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association Between age or Duration of Diagnosis in Obstructive Hypertrophic Cardiomyopathy and Response to Mavacamten Treatment: Exploratory Analysis of the EXPLORER-HCM Trial

梗阻性肥厚型心肌病中年龄或确诊时间与Mavacamten治疗反应关系的关联:EXPLORER-HCM试验的探索性分析

2024-12-070
PRE
Beta blockers and calcium channel blockers in pre-symptomatic patients with hypertrophic cardiomyopathy: prevalence, discontinuation, and effectiveness

肥厚型心肌病无症状患者的β受体阻滞剂和钙通道阻滞剂:患病率、停药情况及疗效

2024-11-120
PRE
Investigating the natural history and risk factors underlying deterioration in early-stage hypertrophic cardiomyopathy: findings from SOLENOID

探究早期肥厚型心肌病恶化背后的自然史及危险因素:SOLENOID研究的结果

2024-11-120
PRE
Limited Concordance of Core Lab Left Ventricular Ejection Fraction With Automated Assessments: A Sub-Study From VALOR-HCM
2023-11-070
PRE
Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial
2023-10-0138
OA